Business Wire

Greene Tweed Achieves Nadcap Accreditation for Non-Metallic Materials Testing

Jaa

Greene Tweed’s Central Engineering (CE) Materials Test Lab recently completed its final Nadcap accreditation audit for Non-Metallic Materials Testing (NMMT) of composite materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180717005200/en/

Greene Tweed Achieves Nadcap Accreditation (Photo: Greene Tweed)

Greene Tweed Achieves Nadcap Accreditation (Photo: Greene Tweed)

In support of Aerospace’s strategic initiative, this positions Greene Tweed as one of a select few aerospace companies who have attained this accreditation as validation of our materials testing capabilities and our position as a composite solutions provider. To achieve this standard, Greene Tweed’s CE lab completed a comprehensive audit against the highest standards for special process controls, test completion, and validation.

This in-house accreditation adds to Greene Tweed’s responsiveness to new product development requests while expanding production material and customer product certification capabilities. It also enhances Greene Tweed’s capability to meet the increasing demand for composite components in new aircraft.

“The sustained hard work, talent, and dedication of the Greene Tweed CE team made this advanced testing capability a reality,” said Christine Fuller, CE Materials Lab Supervisor. “This new Nadcap accreditation demonstrates the adaptability of the CE team in response to changing market requirements, and its continued focus on quality.”

Jeff Sweinhart, Nadcap NMMT Project Leader, said, “This accreditation adds Greene Tweed to an exclusive list of Aerospace industry suppliers who have achieved this level of testing recognition. This achievement is a testimony to CE’s continued commitment to quality and accuracy in our laboratory operations, capabilities, and data outputs.”

Nadcap (National Aerospace and Defense Contractors Accreditation Program) is a global cooperative accreditation program for aerospace engineering, defense, and related industries. The Nadcap program is administered by the Performance Review Institute (PRI), and was established in 1990 by SAE International.

About Greene Tweed

Greene Tweed is a leading global manufacturer of high-performance seals and engineered components. Combining more than 150 years of technical expertise and commercial knowledge in a variety of markets, Greene Tweed collaborates with customers to develop innovative solutions that meet challenging performance requirements and reduce total cost of ownership.

We offer worldwide design and manufacturing expertise, solving your critical challenges through the development of custom-designed, leading-edge components. Greene Tweed products are sold and distributed worldwide. For additional information, contact Greene Tweed at +1.215.256.9521, or visit our website at www.gtweed.com.

Contact information

Greene Tweed
Chris Aldred, +1.267.932.5389
Corporate Marketing
caldred@gtweed.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Veristat Congratulates Agios Pharmaceuticals on the FDA Approval of TIBSOVO®20.8.2018 11:00Tiedote

Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH1 mutation. Veristat is honored to have supported Agios with the preparation of the New Drug Application (NDA) for ivosidenib. We congratulate Agios on the approval of this ground-breaking therapy for patients with this life-threatening malignancy. Veristat began working with Agios on this compound five years ago, providing statistical and medical writing support for their phase I study for ivosidenib which led to the recent approval. Veristat’s support continued through the preparation of the NDA submission. “Over the last fi

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year20.8.2018 11:00Tiedote

Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has accelerated its growth in size, geographic reach and ability to successfully guide clinical trials through the development process to regulatory approval. “Veristat’s ability to achieve this national recognition and to remain on this list for 4 consecutive years highlights our sustainability, innovation and unfaltering commitment to consistently delivering the highest quality clinical development and regulatory submission services to our clients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “The meaningful impact that our teams provide to our clients and to lives of the patients their programs benefit is astounding. In 2018, our teams supported five regulatory submissions that were submitted to the US Food & Dru

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)20.8.2018 10:00Tiedote

Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 August 2018. The primary data from these studies have contributed to a positive label update for dabigatran etexilate (Pradaxa®) in the European Union (EU). The primary RE-DUAL PCITM trial investigated anticoagulation in patients with non-valvular atrial fibrillation (AF) following percutaneous coronary intervention (PCI) and stent placement. Data showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with dabigatran etexilate when compared to triple therapy with warfarin without compromise on efficacy.1,2 GLORIATM-AF is a large, prospective, observational study program run in over 40 countries worldwide. The primary analysis of nearly 5000 AF patients treated with dabiga

Alipay Launches World’s First Paperless Tax Refund Service in South Korea20.8.2018 06:24Tiedote

Alipay, the world’s leading mobile payment and lifestyle platform operated by Ant Financial Services Group, announced that it has partnered with Global Tax Free (“GTF”), a tax refund agency, to launch the world’s first paperless mobile tax refund function in South Korea. Alipay has consistently been at the forefront of innovation that supports mobile tax refund solutions globally. In early 2017, Alipay initiated a real-time tax refund service in Europe which enabled users to instantly receive tax rebates in their Alipay accounts after scanning their Alipay QR code at airport tax counters. The newly introduced tax refund service in South Korea further simplifies the process by enabling Chinese tourists to apply for and claim tax rebates on their mobile phone app, skipping in-city and airport tax refund counters altogether. After scanning their passports at self-service kiosks prior to leaving South Korea, Chinese tourists can process tax rebates and immediately receive RMB refunds by us

Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL16.8.2018 22:02Tiedote

Manchester United (NYSE:MANU) has today announced a major milestone on its digital transformation journey with HCL Technologies, with the successful launch of the Manchester United Official app powered by HCL’s digital experience platform. The launch is part of the ongoing digital transformation of the club to provide a real-time, engaging, personalized, and unified experience to Manchester United’s 659 million global followers, which supports the club’s strategy to become a Digital Sports Enterprise. At the heart of this transformation is the digital platform developed by HCL, providing the club with a single view of fans across web and app touchpoints, offering fans a one-stop shop for everything Manchester United. Manchester United’s Group Managing Director Richard Arnold comments: “This app will allow our 659 million Manchester United followers to easily connect to the club they love, wherever they are in the world. Fans will now have the opportunity to follow all Manchester United

4K 4Charity Fun Run Announces Open Registration for IBC201816.8.2018 20:41Tiedote

AWS Elemental, an Amazon Web Services (AWS) company, today announced that the fifth annual 4K 4Charity Fun Run at IBC Show will take place at 7:00 a.m. local time on Saturday, Sept. 15 at Amstelpark in Amsterdam. Registration is open at https://4k4charity.com/ibc. Among the non-profits supported by the 4K 4Charity Fun Run at IBC Show is Amsterdam-based StichtingNewTechKids, which provides computer science education for girls, minorities, and economically challenged youth in the Netherlands. The organization supports a computer science teacher training program for primary school teachers with proceeds from 4K 4Charity. Also supported is Iridescent, a global education non-profit that empowers underrepresented young people to become innovators and leaders through engineering and technology. Through their two programs, Curiosity Machine AI Family Challenge and Technovation, Iridescent introduces underserved communities to new technologies and empowers and equips them to apply those technol

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme